Search tips
Search criteria 


Logo of procrsmedFormerly medchtJournal of the Royal Society of MedicineProceedings of the Royal Society of Medicine
Proc R Soc Med. 1976 October; 69(10): 747–749.
PMCID: PMC1864661

The role of immunology in the diagnosis, prognosis and treatment planning of oral cancer.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (538K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aurelian L, Davis HJ, Julian CG. Herpesvirus type 2-induced, tumor-specific antigen in cervical carcinoma. Am J Epidemiol. 1973 Jul;98(1):1–9. [PubMed]
  • Baldwin RW, Embleton MJ, Price MR. Inhibition of lymphocyte cytotoxicity for human colon carcinoma by treatment with solubilized tumour membrane fractions. Int J Cancer. 1973 Jul 15;12(1):84–92. [PubMed]
  • Baldwin RW, Price MR, Robins RA. Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nat New Biol. 1972 Aug 9;238(84):185–186. [PubMed]
  • Currie GA, McElwain TJ. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Br J Cancer. 1975 Feb;31(2):143–156. [PMC free article] [PubMed]
  • Duff R, Doller E, Rapp F. Immunologic manipulation of metastases due to herpesvirus transformed cells. Science. 1973 Apr 6;180(4081):79–81. [PubMed]
  • Epstein MA. Implications of a vaccine for the prevention of Epstein-Barr virus infection: ethical and logistic considerations. Cancer Res. 1976 Feb;36(2 Pt 2):711–714. [PubMed]
  • Hellström KE, Hellström I. Immunological enhancement as studied by cell culture techniques. Annu Rev Microbiol. 1970;24:373–398. [PubMed]
  • Hollinshead AC, Tarro G. Soluble membrane antigens of lip and cervical carcinomas: reactivity with antibody for herpesvirus nonvirion antigens. Science. 1973 Feb 16;179(4074):698–700. [PubMed]
  • Laufs R, Steinke H. Vaccination of non-human primates against malignant lymphoma. Nature. 1975 Jan 3;253(5486):71–72. [PubMed]
  • Lehner T, Wilton JM, Shillitoe EJ, Ivanyi L. Cell-mediated immunity and antibodies to Herpesvirus hominis type 1 in oral leukoplakia and carcinoma. Br J Cancer. 1973 May;27(5):351–361. [PMC free article] [PubMed]
  • Olkowski ZL, Wilkins SA., Jr T-lymphocyte levels in the peripheral blood of patients with cancer of the head and neck. Am J Surg. 1975 Oct;130(4):440–444. [PubMed]
  • PREHN RT, MAIN JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957 Jun;18(6):769–778. [PubMed]
  • Rapp F, Reed C. Experimental evidence for the oncogenic potential of herpes simplex virus. Cancer Res. 1976 Feb;36(2 Pt 2):800–806. [PubMed]
  • Rawls WE, Adam E, Melnick JL. An analysis of seroepidemiological studies of herpesvirus type 2 and carcinoma of the cervix. Cancer Res. 1973 Jun;33(6):1477–1482. [PubMed]
  • Sabin AB, Tarro G. Herpes simplex and herpes genitalis viruses in etiology of some human cancers. Proc Natl Acad Sci U S A. 1973 Nov;70(11):3225–3229. [PubMed]
  • Thiry L, Sprecher-Goldberger S, Tack L, Jacques M, Stienon J. Comparison of the immunogenicity of hamster cells transformed by adenovirus and Herpes simplex virus. Cancer Res. 1975 Apr;35(4):1022–1029. [PubMed]

Articles from Proceedings of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press